Anson Funds Management LP purchased a new position in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 793,835 shares of the company's stock, valued at approximately $992,000. Anson Funds Management LP owned about 1.23% of SELLAS Life Sciences Group at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Renaissance Technologies LLC bought a new stake in SELLAS Life Sciences Group in the 2nd quarter worth approximately $39,000. State Street Corp increased its position in SELLAS Life Sciences Group by 30.2% during the third quarter. State Street Corp now owns 174,529 shares of the company's stock valued at $218,000 after acquiring an additional 40,500 shares during the last quarter. Finally, XTX Topco Ltd bought a new position in SELLAS Life Sciences Group in the third quarter valued at about $78,000. 17.38% of the stock is owned by institutional investors.
SELLAS Life Sciences Group Stock Up 3.6 %
NASDAQ:SLS traded up $0.04 on Friday, hitting $1.14. The stock had a trading volume of 1,329,272 shares, compared to its average volume of 1,096,095. SELLAS Life Sciences Group, Inc. has a 52-week low of $0.50 and a 52-week high of $1.72. The stock has a market cap of $80.23 million, a price-to-earnings ratio of -1.65 and a beta of 2.39. The business's 50-day simple moving average is $1.21 and its two-hundred day simple moving average is $1.24.
About SELLAS Life Sciences Group
(
Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
See Also
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
